TAO Synergies Inc.
About TAO Synergies Inc.
TAO Synergies Inc is mainly focused on developing a product platform based on its drug candidate, Bryostatin-1, for the treatment of Alzheimer's disease. The company is also evaluating Bryostatin-1 for other neurodegenerative and cognitive conditions, including Fragile X syndrome and Multiple Sclerosis, which have progressed through pre-clinical testing.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $299.1K
- Net income
- -$28.7M
- Total assets
- $25.8M
- Market cap
- $28.5M
- Gross margin
- 87.2%
- Operating margin
- -3025.2%
- Net margin
- -9609.2%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $299.1K
- Cost of revenue
- $38.3K
- Gross profit
- $260.8K
- Operating expenses
- $9.3M
- Operating income
- -$9.0M
- Income tax
- $0
- Net income
- -$28.7M
- EPS (basic)
- $-8.81
- EPS (diluted)
- $-8.81
Balance sheet
- Total assets
- $25.8M
- Current assets
- $25.4M
- Total liabilities
- $3.9M
- Current liabilities
- $1.8M
- Shareholders’ equity
- $21.1M
Cash flow
- Operating cash flow
- -$6.4M
- Investing cash flow
- -$28.9M
- Financing cash flow
- $23.1M
- Net cash flow
- -$12.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $28.5M
- EPS (diluted)
- $-8.81
- Shares outstanding
- 7.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $28.7M in FY2025.
- Gross margin of 87.2%, net margin -9609.2%.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review TAO Synergies Inc..
